Welcome to the e-CCO Library Archive!
M. Muscat1, N.A. Kennedy1, J. Chang1, F. Fascí Spurio1, J. Satsangi1, I.D. Arnott1, K. Kingstone2, C. Lees1, 1Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, 2Western General Hospital, Clinical Biochemistry, Edinburgh, United Kingdom
Management of loss of response to infliximab. Results of a descriptive study of a cohort of inflammatory bowel disease patients.
E. Ferrand1, D. Ternant2, L. Picon1, D. Moussata1, A. Aubourg*1
1CHRU Tours, Hepatogastroenterology, Tours, France, 2CHRU Tours, Pharmacology, Tours, France
The prevalence and clinical characteristics of refractory Crohn's disease in South China
Y. He, P. Xu, Z. Zeng, B. Chen, R. Mao, K. Chao, M. Chen, The First Affiliated Hospital of SunYat-Sen University, Gastroenterology, Guangzhou, China
M. Di Girolamo1, A. Scarcelli1, A. Bertani1, A. Sartini1, A. Merighi1, E. Villa1, 1Policlinico Modena, Italy
Adalimumab long-term effectiveness in adults with Crohn's Disease: Observational data from the PYRAMID registry
E.V. Loftus Jr*1, G. D'Haens2, W. Reinisch3, 4, J. Satsangi5, R. Panaccione6, R. Thakkar7, S. Eichner8, K. Wallace9, A. Deshmukh10, S. Wang11, M. Skup11, J. Chao11, Y. Bao11
1Mayo Clinic, Division of Gastroenterology & Hepatology, Rochester, United States, 2Academic Medical Center, Gastroenterology, Amsterdam, Netherlands, 3Medical University of Vienna, Internal Medicine, Vienna, Austria, 4McMaster University, Internal Medicine, Hamilton, Canada, 5Western General Hospital, Edinburgh, United Kingdom, 6University of Calgary, Medicine, Calgary, Canada, 7AbbVie Inc., Global Pharmaceutical Research & Development , North Chicago, IL, United States, 8AbbVie Inc., Global Medical Affairs, North Chicago, IL, United States, 9AbbVie Inc., Immunology/Gastroenterology, North Chicago, IL, United States, 10AbbVie Inc., Statistics, North Chicago, IL, United States, 11AbbVie Inc., Global Health Economics and Outcomes Research, North Chicago, IL, United States
Deep clinical remission in patients with Ulcerative Colitis: Evaluating the effects of vedolizumab on various combinations of endoscopic and patient-reported outcomes
W. Sandborn*1, J.-F. Colombel2, R. Panaccione3, K. Lasch4, S. Sankoh5, B. Abhyankar6
1University of California San Diego, Division of Gastroenterology, La Jolla, United States, 2Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States, 3University of Calgary, Department of Medicine, Calgary, Canada, 4Takeda Pharmaceuticals International, Inc., GI Medical Affairs, US Region, Deerfield, United States, 5Takeda Pharmaceuticals International Co., Global Statistics, Cambridge, United States, 6Takeda Global Research & Development Centre (Europe) Ltd., GI Clinical Science, London, United Kingdom
Table
The presence of fistulae at baseline does not increase the incidence of adverse events in patients with Crohn's disease in the infliximab ENCORE registry
G. D'Haens1, W. Reinisch2, J.-F. Colombel3, J. Panes4, S. Ghosh5, C. Prantera6, S. Lindgren7, D.W. Hommes8, Z. Huang9, S. Huyck10, D.K. Chitkara11, 1Academic Medical Center, Inflammatory Bowel Disease Centre, Amsterdam, Netherlands, 2Medical University, Department of Internal Medicine III, Vienna, Austria, 3Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States, 4Hospital Clinic I Provincial, Department of Inflammatory Disease, Barcelona, Spain, 5University of Calgary, Department of Medicine, Calgary, Canada, 6AO San Camillo Forlianini, Gastroenterology Operative Unit, Rome, Italy, 7University Hospital MAS, Department of Gastroenterology, Malmö, Sweden, 8University of California Los Angeles, Center for Inflammatory Bowel Diseases, Los Angeles, United States, 9Merck Sharp & Dohme, Department of Epidemiology, Kenilworth, United States, 10Merck Sharp & Dohme, Department of Statistics, Merck Research Laboratories, Kenilworth, United States, 11Merck Sharp & Dohme, Department of Clinical Research, Kenilworth, United States
A. Mikocka-Walus1, J. Andrews2, 1University of South Australia, Nursing and Midwifery, Adelaide, Australia, 2Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia
Clinical relevance of faecal calprotectin variability in Inflammatory Bowel Disease
V. Kristensen*1, 2, G.H. Malmstrøm1, V. Skar1, B. Moum2, 3
1Lovisenberg Diakonale Hospital, Unger-Vetlesen`s Institute, Oslo, Norway, 2University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 3Oslo University Hospital, Department of Gastroenterology, Oslo, Norway
The one-year efficacy of infliximab does not depend on the timing of biological therapy in ulcerative colitis
T. Molnar1, A. Bálint1, T. Nyári2, K. Farkas1, R. Bor1, Z. Szepes1, F. Nagy1, P. Miheller3, Á. Csontos3, G. Horváth4, P.L. Lakatos5, P.A. Golovics5, K. Palatka6, T. Wittmann1, 1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary, 3Semmelweis University, 2nd Department of Medicine, Budapest, Hungary, 4Semmelweis Health Center, Department of Gastroenterology, Miskolc, Hungary, 5Semmelweis University, First Department of Medicine, Budapest, Hungary, 6University of Debrecen, 2nd Department of Medicine, Debrecen, Hungary
K. Lorinczy1, P.L. Lakatos2, Á. Salamon3, A. Nemes3, B. Fekete1, O. Terjék1, Á. Csontos1, T. Pere3, L. Herszényi1, Z. Tulassay1, P. Miheller1, 1Semmelweis University, 2nd Department of Internal Medicine, Budapest, Hungary, 2Semmelweis University, 1nd Department of Internal Medicine, Budapest, Hungary, 3János Balassa Tolna County Hospital, Department of Gastroenterology, Szekszárd, Hungary
Postoperative complications after ileo-caecal resection for Crohn's Disease: a prospective multicentre study.
M. Fumery*1, P. Seksik2, M. Chirica3, J.-M. Gornet4, G. Boschetti5, E. Cotte6, A. Buisson7, M. Nachury8, P. Zerbib9, X. Treton10, Y. Panis11, P. Marteau12, K. Pautrat13, C. Sabbagh14, J. filippi15, M. Allez4
1Amiens University Hospital, Hepatogastroenterology, Amiens, France, 2Hopital Saint Antoine , Gastroenterology , Paris, France, 3APHP, Hopital Saint Louis, Digestive surgery, Paris, France, 4APHP, Hopital Saint Louis, Department of Gastroenterology, Paris, France, 5CHU Lyon, Gastroenterology, Lyon, France, 6CHU Lyon, Digestive surgery, Lyon, France, 7CHU de Clermont-Ferrand, Department of Gastroenterology, Clermont-Ferrand, France, 8CHU Lille, Gastroenterology, Lille, France, 9CHU Lille, Digestive surgery, Lille, France, 10Beaujon Hospital, Department of Gastroenterology, Clichy la Garenne, France, 11Beaujon Hospital, Colorectal Surgery, Clichy, France, 12Hopital Lariboisiere, Gastroenterology, Paris, France, 13Hopital Lariboisiere, Digestive surgery, Paris, France, 14Amiens University Hospital, Digestive Surgery, Amiens, France, 15CHU de Nice, Department of Gastroenterology, Nice, France